HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Atypical hemolytic uremic syndrome — Clinical Guidelines

Overview

Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, primarily due to dysregulation of the alternative complement pathway 1 5.

Diagnosis

Clinical triad: Microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury 1 6.

Genetic testing: Recommended for identifying mutations in complement regulatory genes 1 3.

Complement analysis: Investigate complement dysregulation, including anti-factor H antibody detection 4.

Exclusion of other causes: Essential to rule out other thrombotic microangiopathies 9.

Management

First-line treatment:

- Eculizumab: Anti-C5 complement monoclonal antibody, effective in reducing LDH and creatinine levels 3. - Plasma therapy: Plasma exchange or infusion may still be used initially 1 4.

Adjunctive treatments:

- Liver transplantation: Considered in refractory cases 1. - Monitoring: Regular assessment of complement blockade efficacy and potential complications like meningococcal infection 4.

Special Populations

Pregnancy: Specificities and challenges in diagnosis and management noted, requiring tailored approaches 2.

Pediatrics: Early diagnosis crucial; international consensus recommends complement investigations and timely initiation of eculizumab 4.

Comorbidities: Management in contexts like kidney transplantation or hypertensive emergencies requires careful consideration and may involve novel therapeutic strategies 2.

Key Recommendations

Initiate genetic testing for complement pathway mutations in suspected aHUS cases to guide targeted therapy (Evidence: Moderate 1 3).

Consider early initiation of eculizumab for severe or refractory aHUS to address underlying complement dysregulation (Evidence: Moderate 3 4).

Monitor for and prevent meningococcal infections in patients on complement blockade therapy (Evidence: Expert opinion 4).

Develop and apply diagnostic criteria to facilitate early diagnosis and timely treatment initiation, particularly in pediatric populations (Evidence: Expert opinion 6).

References

1 Vaisbich MH, Andrade LGM, Barbosa MINH, Castro MCR, Miranda SMC, Poli-de-Figueiredo CE et al.. Recommendations for diagnosis and treatment of Atypical Hemolytic Uremic Syndrome (aHUS): an expert consensus statement from the Rare Diseases Committee of the Brazilian Society of Nephrology (COMDORA-SBN). Jornal brasileiro de nefrologia 2025. link 2 Karoui KE. [Recent data on atypical hemolytic uremic syndrome associated with pregnancy, kidney transplantation or hypertensive emergency]. Nephrologie & therapeutique 2024. link 3 Thomas K, Ananthula A, Lopez-Flores R, Toro AD, Chapple AG, Loch M. The Use of Eculizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in an Academic Hematology Center. The Permanente journal 2023. link 4 Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A et al.. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatric nephrology (Berlin, Germany) 2016. link 5 Sadler JE. Atypical HUS may become a diagnosis of inclusion. Blood 2015. link 6 Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y et al.. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Pediatrics international : official journal of the Japan Pediatric Society 2014. link 7 Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y et al.. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Clinical and experimental nephrology 2014. link 8 Mehta K, More V, Chitale A, Khubchandani S. Atypical hemolytic uremic syndrome with membranoproliferative glomerulonephritis. Indian pediatrics 2013. link 9 Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?. Hematology. American Society of Hematology. Education Program 2012. link

Atypical hemolytic uremic syndrome